Marijo Bilusic, M.D., Ph.D.
Dr. Bilusic directs the NIH Hematology Oncology Fellowship, which provides fellows with a strong clinical grounding in hematology and oncology as well as a comprehensive introduction to clinical, laboratory and translational research. His current research interests focus on tumor immunology and development of treatment options for prostate cancer and other genitourinary tumors using novel targeted agents, therapeutic cancer vaccines, antibodies, or immune modulators.
Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1)Open - RecruitingNCI Protocol ID NCI-18-C-0076Investigator Marijo Bilusic, M.D., Ph.D.
Treatment of Patients with Castration Resistant Prostate Cancer using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy VaccinesOpen - RecruitingNCI Protocol ID NCI-18-C-0073Investigator Marijo Bilusic, M.D., Ph.D.Share this trial: Referral Contacts
Contact Name Phone Number Sheri McMahon 240.760.7968
Dr. Bilusic's research interests focus on tumor immunology and development of novel immunotherapy approaches for prostate cancer and other genitourinary tumors using therapeutic cancer vaccines, antibodies, or immune modulators capable of inducing the immune system to recognize and kill cancer cells. He is evaluating multiple different therapeutic cancer vaccine platforms, including MVA-brachyury-TRICOM, fowlpox-brachyury-TRICOM , Ad5[E1-, E2b-]-MUC1, Ad5[E1-, E2b-]-brachyury, and Ad5[E1-, E2b-]-PSA. He is also leading a multicenter study to treat men with biochemically recurrent prostate cancer with a combination of metformin and bicalutamide.
Selected Recent Publications
- Hum Vaccin Immunother. 13(11): 2561-2574, 2017. [ Journal Article ]
- Clin Cancer Res. 23(22): 6764-6770, 2017. [ Journal Article ]
- Clin Genitourin Cancer. 15(3): e337-e343, 2016. [ Journal Article ]
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.Eur Urol. 68(6): 959-67, 2015. [ Journal Article ]
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.Cancer Immunol Immunother. 63(3): 225-34, 2014. [ Journal Article ]
Dr. Marijo Bilusic received a his M.D. degree from the University of Zagreb School of Medicine in Croatia and completed his Ph.D. training at the University of Split School of Medicine in Croatia. He then completed a clinical fellowship in medical oncology and hematology at the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI), in Bethesda, MD. In addition, he completed a postdoctoral research fellowship in physiological genomics at the Medical College of Wisconsin's Human and Molecular Genetics Center in Milwaukee, WI. Dr. Bilusic served as an assistant professor (genitourinary medical oncology) at the Fox Chase Cancer Center/Temple Health from 2012 – 2016 and then joined the NCI Medical Oncology Service/Genitourinary Malignancy Branch in 2016. He is board certified in medical oncology, hematology and internal medicine. In 2017 Dr. Bilusic received the NIH Director's Award as a member of NIH Hematology Oncology Fellowship Team for extraordinary resourcefulness and initiative in merging the NCI's Medical Oncology Fellowship and the NHLBI's Hematology Fellowship programs to implement the new NIH Hematology Oncology Fellowship Program.